RxDoctor Payments Data

Alexander Whitley, MD

Radiation Oncology · Montgomery, ALNPI 1063648509

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (46.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 74.0% of it on its own, with 18 other manufacturers making up the rest. Among radiation oncology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$440,628in general payments, 2019–2025

Across 410 payments — averaging $1074.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$326K
  • Novocure Inc.$85K
  • Novocure GmbH$16K
  • Siemens Medical Solutions USA, Inc.$12K
  • Boston Scientific$335
  • Novartis$272
  • plus $1K from 13 others
$17,000in research payments, 2019–2025

Across 2 payments — averaging $8500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novocure GmbH$17K

What the payments were for

  • Consulting fees$204,28846%
  • Speaking & faculty fees$199,53045%
  • Travel & lodging$29,0557%
  • Food & beverage$7,7432%
  • Education$130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$440,628 in reported general payments places this provider in the 95th percentile of 87 radiation oncology providers in Alabama.

See all radiation oncology providers in Alabama

Medicare billing

Part B allowed, 2024
$933,403
Medicare patients
335
Services billed
4,676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mometasone Furoate76$2,356
SsdSilver Sulfadiazine27$1,098
Tamsulosin Hcl61$1,096
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen32$775
Dexamethasone17$612
Ondansetron OdtOndansetron11$192
Methylprednisolone13$144

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →